Skip to main content
SYMTUZA® logo
  • Important Safety Information
  • Prescribing Information
  • Patient Site
  • home
  • HIV Treatment 
    Considerations
    • DHHS Guidelines:
      Weight
    • Patients at Risk:
      Weight
    • Real-World Data:
      INSTI vs PI
    • Patient POV
    • DHHS Guidelines:
      Rapid Initiation
    • Patients at Risk:
      HGBR
    • M184V/I Prevalence
  • Efficacy
    • Treatment-Naïve
      Patients
    • Rapid Initiation
      Patients
    • Virologically
      Suppressed Patients
  • Resistance 
    Summary
  • Safety & 
    Tolerability
    • Adverse Event 
      Profile
    • GI Tolerability
    • Weight Change
    • Real-World Data: 
      SYMTUZA® vs 
      BIC/FTC/TAF
    • Neuropsychiatric 
      Tolerability
    • Patient Satisfaction
  • Dosing & 
    Administration
    • Dosing
    • Patient Satisfaction
    • STR Pill Guide
    • Coadministration
    • Darunavir Dosing
      Simplified
  • Support & Treatment 
    Resources
    • Resources
    • SYMply Start®
    • CoverMyMeds®
    • Request
      Samples
    • Coverage in
      Your Area
    • Switch DRV Patients
      to SYMTUZA®
  • Important Safety Information
  • Patient Site
  • Prescribing Information

Site Map

  • Important Safety Information
  • Prescribing Information
  • Patient Site
  • Home
  • HIV Treatment Considerations
    • DHHS Guidelines: Weight
    • Patients at Risk: Weight
    • Real-World Data: INSTI vs PI
    • Patient POV
    • DHHS Guidelines: Rapid Initiation
    • Patients at Risk: HGBR
    • M184V/I Prevalence
  • Efficacy
    • Treatment-Naïve Patients
    • Rapid Initiation Patients
    • Virologically Suppressed Patients
  • Resistance Summary
  • Safety & Tolerability
    • Adverse Event Profile
    • GI Tolerability
    • Weight Change
    • Real-World Data: SYMTUZA® vs BIC/FTC/TAF
    • Neuropsychiatric Tolerability
    • Patient Satisfaction
  • Dosing & Administration
    • Dosing
    • Patient Satisfaction
    • STR Pill Guide
    • Coadministration
    • Darunavir Dosing Simplified
  • Support & Treatment Resources
    • Resources
    • SYMply Start®
    • CoverMyMeds®
    • Request Samples
    • Coverage in Your Area
    • Switch DRV Patient to SYMTUZA®
  • Legal Notice
  • Privacy Policy
  • Medical Information Center
  • Contact Us
  • Site Map
  • CoverMyMeds
  • Find Coverage
INDICATION

SYMTUZA® is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatric patients weighing at least 40 kg:

  • who have no prior antiretroviral treatment history or
  • who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least 6 months and have no known substitutions associated with resistance to darunavir or tenofovir.
IMPORTANT SAFETY INFORMATION

BOXED WARNING: POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B

  • Severe acute exacerbations of hepatitis B (HBV) have been reported in patients who are coinfected with HIV-1 and HBV and have discontinued products containing emtricitabine and/or tenofovir disoproxil fumarate (TDF) and may occur with discontinuation of SYMTUZA®.
    Action: Monitor hepatic function with both clinical and laboratory follow-up for at least several months in patients who are coinfected with HIV-1 and HBV and discontinue SYMTUZA®. If appropriate, anti-hepatitis B therapy may be warranted.


CONTRAINDICATIONS

  • Darunavir and cobicistat are both inhibitors and substrates of the cytochrome P450 3A (CYP3A) isoform. SYMTUZA® should not be co-administered with medicinal products that are highly dependent on CYP3A for clearance and for which increased plasma concentrations are associated with serious and/or life-threatening events. In addition, co-administration of SYMTUZA® with CYP3A inducers is expected to lower plasma concentrations of darunavir and cobicistat which may lead to loss of efficacy of darunavir and development of resistance.

    Action: Examples of drugs that are contraindicated for co-administration with SYMTUZA® due to the potential for serious and/or life-threatening events or loss of therapeutic effect are listed below: alfuzosin, carbamazepine, colchicine (in patients with renal and/or hepatic impairment), dronedarone, elbasvir/grazoprevir, ergot derivatives (such as: dihydroergotamine, ergotamine, methylergonovine), ivabradine, lomitapide, lovastatin, lurasidone, oral midazolam, naloxegol, phenobarbital, phenytoin, pimozide, ranolazine, rifampin, St. John’s wort (Hypericum perforatum), sildenafil for pulmonary arterial hypertension, simvastatin, and triazolam.


WARNINGS AND PRECAUTIONS

  • Hepatotoxicity: Drug-induced hepatitis (e.g., acute hepatitis, cytolytic hepatitis) and cases of liver injury, including some fatalities, have been reported in patients receiving darunavir, a component of SYMTUZA®. Patients with pre-existing liver dysfunction, including chronic active hepatitis B or C, have an increased risk for liver function abnormalities, including severe hepatic adverse reactions.

    Action: Monitor liver function prior to initiating and during therapy, especially in patients with underlying chronic hepatitis, cirrhosis, or in patients who have pretreatment elevations of transaminases. Patients with evidence of new or worsening liver function should consider discontinuing SYMTUZA®. SYMTUZA® is not recommended in patients with severe hepatic impairment (Child-Pugh Class C).

  • Severe Skin Reactions: In patients receiving darunavir, a component of SYMTUZA®, severe skin reactions may occur, including Stevens-Johnson syndrome, toxic epidermal necrolysis, drug rash with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis. These include conditions accompanied by fever and/or elevations of transaminases.

    Action: Discontinue SYMTUZA® immediately if signs or symptoms of severe skin reactions develop. These can include but are not limited to severe rash or rash accompanied with fever, general malaise, fatigue, muscle or joint aches, blisters, oral lesions, conjunctivitis, hepatitis, and/or eosinophilia.

  • Risk of Serious Adverse Reactions or Loss of Virologic Response Due to Drug Interactions: Consult the full Prescribing Information prior to and during treatment for potential drug interactions.

  • Immune Reconstitution Syndrome: Patients receiving SYMTUZA® may develop new onset or exacerbations of immune reconstitution syndrome.

  • New Onset or Worsening Renal Impairment: Postmarketing cases of renal impairment, including acute renal failure, proximal renal tubulopathy (PRT), and Fanconi syndrome have been reported with tenofovir alafenamide (TAF)-containing products; while most of these cases were characterized by potential confounders that may have contributed to the reported renal events, it is also possible these factors may have predisposed patients to tenofovir-related adverse events. SYMTUZA® is not recommended in patients with estimated creatinine clearance below 30 mL per minute. Patients taking tenofovir prodrugs who have impaired renal function and those taking nephrotoxic agents including nonsteroidal anti-inflammatory drugs are at increased risk of developing renal-related adverse reactions.

    Action: Prior to initiating or during treatment, on a clinically appropriate schedule, monitor serum creatinine, estimated creatinine clearance, urine glucose, and urine protein in all patients. In patients with chronic kidney disease, also assess serum phosphorus. Discontinue SYMTUZA® in patients who develop clinically significant decreases in renal function or evidence of Fanconi syndrome. Patients who experience a confirmed increase in serum creatinine of greater than 0.4 mg/dL should be closely monitored for renal safety.

  • Sulfa Allergy: Darunavir contains a sulfonamide moiety. The incidence and severity of rash were similar in subjects with or without a history of sulfonamide allergy.

    Action: Monitor patients with a known sulfonamide allergy.

  • Lactic Acidosis/Severe Hepatomegaly With Steatosis: Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including emtricitabine, a component of SYMTUZA®, and tenofovir disoproxil fumarate (TDF), another prodrug of tenofovir, alone or in combination with other antiretrovirals.

    Action: Discontinue SYMTUZA® in any patient who develops clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity.

  • Diabetes Mellitus/Hyperglycemia: New-onset or exacerbations of pre-existing diabetes mellitus and hyperglycemia have been reported in patients receiving protease inhibitors.

    Action: Initiation or dose adjustments of insulin or oral hypoglycemic agents may be required.

  • Fat Redistribution: Redistribution and/or accumulation of body fat have been observed in patients receiving antiretroviral therapy.

  • Hemophilia: Patients with hemophilia may develop an increase in bleeding events.


ADVERSE REACTIONS

  • The most common clinical adverse reactions (all grades) occurring in at least 2% of treatment-naïve patients were diarrhea, rash,* nausea, fatigue, headache, abdominal discomfort, and flatulence.

*Includes pooled reported terms: dermatitis, dermatitis allergic, erythema, photosensitivity reaction, rash, rash generalized, rash macular, rash maculopapular, rash morbilliform, rash pruritic, toxic skin eruption, and urticaria.

Grade 2-4 laboratory abnormalities have been reported in patients receiving SYMTUZA®, including elevations in serum creatinine, liver function tests, triglycerides, total cholesterol, low-density lipoproteins, and glucose levels. This is not a complete list of all adverse reactions reported with the use of SYMTUZA®. Please refer to the full Prescribing Information for a complete list of adverse drug reactions.


USE IN SPECIFIC POPULATIONS

  • Pregnancy: SYMTUZA® is not recommended for use during pregnancy and should not be initiated in pregnant individuals because of substantially lower exposures of darunavir and cobicistat during pregnancy.

    Lactation: The Centers for Disease Control and Prevention recommends that HIV-infected mothers in the United States must not breastfeed their infants to avoid risking postnatal transmission of HIV-1 infection.

  • Pediatric Use: The safety and effectiveness of SYMTUZA® have not been established and is not recommended in pediatric patients weighing less than 40 kg.
  • Consult the full Prescribing Information for SYMTUZA® for additional information on the Uses in Specific Populations.

Please see full Prescribing Information, including Boxed WARNING for SYMTUZA®.

cp-62076v10

Distributed by: Janssen Therapeutics, Division of Janssen Products, LP, Titusville, NJ 08560

© Janssen Therapeutics, Division of Janssen Products, LP 2022 07/22 cp-282967v2. All rights reserved.

This site is published by Janssen Therapeutics, Division of Janssen Products, LP, which is solely responsible for its contents. This site is intended for use by healthcare professionals of the United States and Puerto Rico. Janssen Therapeutics, Division of Janssen Products, LP, recognizes that the Internet is a global communications medium; however, laws, regulatory requirements, and medical practices for pharmaceutical products vary from country to country. The Prescribing Information included here may not be appropriate for use outside the United States and Puerto Rico.

Third party trademarks used herein are trademarks of their respective owners.

Legal Notice | Privacy Policy | Medical Information Center | Contact Us | Site Map | CoverMyMeds | Coverage In Your Area | 

Do not sell my personal information

Last Updated June 2022

  • Medical Information Center
  • Contact Us
  • Site Map
  • CoverMyMeds
  • Coverage In Your Area

Last Updated June 2022

Janssen Infectious Diseases & Vaccines logo

EXTERNAL LINK

You are now leaving www.symtuzahcp.com

By clicking “Continue” below, you will be taken to [extlink:external-url], a website that may contain links or references to other websites to which our Privacy Policy may not apply. We encourage you to read the Privacy Policy of every website you visit. Our Privacy Policy can be reviewed by clicking here. You are solely responsible for your interactions with such websites.

Thank you for visiting our site. We hope your visit was informative and enjoyable.

Continue
CANCEL
Loading Common Footer...